In light of recent updates on neoadjuvant enfortumab vedotin plus pembrolizumab for muscle-invasive bladder cancer showing benefit, how should a trimodality bladder-preservation strategy be contextualized?
Do patients who are otherwise suitable for bladder preservation risk forfeiting access to highly effective preoperative systemic therapy, and does a bladder-sparing approach remain a reasonable option in an era of more effective neoadjuvant treatment with EV/pembrolizumab?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Vanderbilt-Ingram Cancer Center
Answered on
The treatment of muscle-invasive bladder cancer. has evolved quickly. Neoadjuvant EVP is absolutely the standard of care in all patients who can receive it. The clinical trials (EV-303/304) used cystectomy as the bladder-directed therapy, and this is the standard of care. Having said that, many pati...
Join for free or sign in to see the full answer